Table 2. Primary and secondary endpoints among patients with versus without prior revascularisation.

	Patients with prior revascularisation				Patients without prior revascularisation				p for interaction
Endpoints	Rivaroxaban monotherapy (n=847) (per patient-year)	Combination therapy (n=850) (per patient-year)	Hazard ratio (95% CI)	p-value	Rivaroxaban monotherapy (n=260) (per patient-year)	Combination therapy (n=258) (per patient-year)	Hazard ratio (95% CI)	p-value
Efficacy endpoints
Primary efficacy endpoint	63 (3.83)	100 (6.18)	0.62 (0.45-0.85)	0.003	26 (5.14)	21 (4.34)	1.19 (0.67-2.12)	0.554	0.055
Death from any cause	29 (1.72)	59 (3.53)	0.49 (0.31-0.77)	0.001	12 (2.28)	14 (2.84)	0.80 (0.37-1.73)	0.565	0.289
Cardiovascular death	17 (1.01)	35 (2.10)	0.48 (0.27-0.86)	0.011	9 (1.71)	8 (1.62)	1.05 (0.40-2.71)	0.925	0.172
Ischaemic stroke	14 (0.84)	22 (1.33)	0.63 (0.32-1.23)	0.171	7 (1.35)	6 (1.23)	1.10 (0.37-3.28)	0.860	0.392
Haemorrhagic stroke	2 (0.12)	12 (0.72)	0.17 (0.04-0.74)	0.007	2 (0.38)	1 (0.20)	1.90 (0.17-20.98)	0.593	0.092
Myocardial infarction	10 (0.60)	6 (0.36)	1.66 (0.60-4.57)	0.320	3 (0.58)	2 (0.41)	1.45 (0.24-8.66)	0.684	0.890
Unstable angina requiring revascularisation	9 (0.54)	16 (0.97)	0.55 (0.25-1.25)	0.150	4 (0.77)	2 (0.41)	1.93 (0.35-10.54)	0.440	0.197
Systemic embolism	1 (0.06)	0 (0)	-	-	1 (0.19)	1 (0.20)	0.96 (0.06-15.29)	0.975	0.995
Safety endpoints
Primary safety endpoint	29 (1.76)	46 (2.85)	0.62 (0.39-0.98)	0.042	6 (1.17)	12 (2.48)	0.47 (0.18-1.26)	0.134	0.633
Any bleeding	116 (7.50)	191 (13.20)	0.57 (0.46-0.72)	<0.001	31 (6.41)	48 (11.14)	0.59 (0.38-0.93)	0.022	0.893
Non-major bleeding	97 (6.17)	162 (10.89)	0.57 (0.44-0.73)	<0.001	25 (5.09)	37 (8.43)	0.62 (0.38-1.04)	0.066	0.760
Data are expressed as n (%). CI: confidence interval